# Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke

Study · id `cardio:ct-nct05035953` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05035953](<https://clinicaltrials.gov/study/NCT05035953>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05035953

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05035953. Randomized; double masking; primary purpose treatment. Start 2021-09-13 (anticipated); primary completion 2023-09-13 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05035953, source copy `cardio:ctgov-nct05035953-2021-09-05`, retrieved 2026-10-26)
- Planned start: 2021-09-13 (anticipated) (ClinicalTrials.gov record NCT05035953, source copy `cardio:ctgov-nct05035953-2021-09-05`, retrieved 2026-10-26)
- Primary completion: 2023-09-13 (anticipated) (ClinicalTrials.gov record NCT05035953, source copy `cardio:ctgov-nct05035953-2021-09-05`, retrieved 2026-10-26)
- Completion: 2024-03-13 (anticipated) (ClinicalTrials.gov record NCT05035953, source copy `cardio:ctgov-nct05035953-2021-09-05`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05035953-2021-09-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke
- Condition: Stroke, Ischemic
- Intervention (Drug): Edaravone Dexborneol
- Intervention (Drug): Placebo
- Lead sponsor: Huashan Hospital
- Lead sponsor class: OTHER
- Collaborator: Shanghai Stroke Association
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Huashan Hospital (`cardio:org-huashan-hospital`)

## Provenance

Content hash: 86a4d8aab556b8d5b4d2c8dcd407b4248abc724a409f2ba6827186c2a82823b9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
